Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | LSS | P48449 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16826120 | 0.92 | PYCR1 (0.45) | EP300GBA1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17887965 | 0.92 | SLC6A2 (0.52) | EP300SLC6A2SLC6A4SLC6A3CXCR3 | |
| SCHEMBL5651526 | 0.91 | GBA1 (0.56) | EP300GBA1SLC6A2SLC6A4USP30 | |
| SCHEMBL31381408 | 0.91 | EP300 (0.41) | EP300GBA1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5650751 | 0.89 | EP300 (0.42) | EP300GBA1SLC6A2SLC6A4TDP1 | |
| Hydrochloric Acid SCHEMBL5570678 | 0.82 | EP300 (0.40) | EP300GBA1TDP1HTR2CHTR2B | |
| SCHEMBL14421947 | 0.80 | EP300 (0.38) | EP300GBA1TDP1HTR2CHTR2B | |
| SCHEMBL16327151 | 0.79 | PYCR1 (0.50) | SLC6A2SLC6A4CXCR3LSS | |
| SCHEMBL4267535 | 0.78 | CXCR3 (0.41) | CXCR3TDP1LSS | |
| SCHEMBL1240985 | 0.78 | PYCR1 (0.51) | CXCR3LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326771-A1 | PIPERAZINE DERIVATIVES USEFUL IN HIV THERAPY | VIIV HEALTHCARE CO (US) | 2025-10-23 | — | — | US | disclosed |
| CN-119487019-A | Piperazine derivatives for HIV therapy | VIIV保健公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2023230541-A1 | PIPERAZINE DERIVATIVES USEFUL IN HIV THERAPY | VIIV HEALTHCARE COMPANY (US) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326771-A1 | PIPERAZINE DERIVATIVES USEFUL IN HIV THERAPY | CCR5, THPO, IL5 | EP300 9/4885GBA1 171/4885SLC6A2 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.